Opening lecture: A pathologist, a radiologist and a hepatologist walked into a bar | Brent Neuschwander-Tetri, MD

International Workshop on NASH Biomarkers 2017

Gilead: RSV | Erik Mogalian

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Janssen: Influenza | Thomas Kakuda, PharmD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Merck: CMV | Cyrus Badshah, MD, PhD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Con Standpoint | Jürgen Rockstroh, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Pro Standpoint | Nancy Reau, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Long Acting Antivirals: Advanced drug delivery | Mark Milad, PharmD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

DDI’s in Aging HCV infected Patients | Elise Smolders, MSc

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

FDA perspective | Kellie Reynolds, PharmD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

HBV therapy & Approaches to Cure | Jordan Feld, MD, MPH

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Clinical Aspects of Pediatric Treatment | Tim Cressey, PhD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Current Challenges in Pediatric Drug Development | Robert Ward, MD, FAAP, FCP

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Current and Future Treatment of CMV | Robin Avery, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Management of DAA Failures | Gregory T. Everson, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Post-LT Renal Failure and HCV Rx | Peter Ferenci, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Obstacles to Treatment: Renal Disease, Ribavirin, DDIs | Michael Charlton, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? | Maria Londoño, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Use of HCV+ Donor Grafts | Didier Samuel, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Achieving SVR in CTP C – MELD Purgatory | Christophe Duvoux, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

When to Treat HCV in a Waiting List Patient? | Stefano Fagiuoli, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? | Xavier Forns, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Treatment Experienced GT3 patient with Cirrhosis | Geoffrey McCaughan, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Is Treatment Cost-effective? | Kosh Agarwal, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Who Should We Treat? What is the “Point-of-No-Return”? | Norah Terrault, MD, MPH, FAASLD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016